Literature DB >> 21827828

Interaction between mineralocorticoid receptor and epidermal growth factor receptor signaling.

Claudia Grossmann1, Michael Gekle.   

Abstract

The mineralocorticoid receptor (MR) is a steroid receptor that physiologically regulates water and electrolyte homeostasis but that can also induce pathophysiological effects in the renocardiovascular system. Classically, the MR acts as a transcription factor at glucocorticoid response elements but additional protein-protein interactions with other signaling cascades have been described. Of these, the crosstalk with EGFR signaling is especially interesting because various vasoactive substances like angiotensin II and endothelin-1 also mediate their pathophysiological effects via the EGFR. Recently, the MR has been shown to interact nongenomically (via transactivation) and genomically with the epidermal growth factor receptor (via altered expression). These interactions seem to contribute to physiological (e.g. salt homeostasis) as well as pathophysiological (e.g. vascular function) MR effects. The current knowledge on the mechanisms of interaction and on the possible cellular and systemic physiological as well as pathophysiological relevance is reviewed in this article.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21827828     DOI: 10.1016/j.mce.2011.07.045

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  6 in total

Review 1.  Aldosterone and the Mineralocorticoid Receptor: Risk Factors for Cardiometabolic Disorders.

Authors:  Rajesh Garg; Gail K Adler
Journal:  Curr Hypertens Rep       Date:  2015-07       Impact factor: 5.369

2.  The selective mineralocorticoid receptor antagonist eplerenone prevents decompensation of the liver in cirrhosis.

Authors:  Barbara Schreier; Anja Wolf; Stefanie Hammer; Sabine Pohl; Sigrid Mildenberger; Sindy Rabe; Michael Gekle; Alexander Zipprich
Journal:  Br J Pharmacol       Date:  2018-06-07       Impact factor: 8.739

Review 3.  Aldosterone and cardiovascular disease: the heart of the matter.

Authors:  B Julie He; Mark E Anderson
Journal:  Trends Endocrinol Metab       Date:  2012-10-03       Impact factor: 12.015

Review 4.  The circadian clock in cancer development and therapy.

Authors:  Loning Fu; Nicole M Kettner
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

5.  Moderate inappropriately high aldosterone/NaCl constellation in mice: cardiovascular effects and the role of cardiovascular epidermal growth factor receptor.

Authors:  Barbara Schreier; Sindy Rabe; Sabrina Winter; Stefanie Ruhs; Sigrid Mildenberger; Bettina Schneider; Maria Sibilia; Michael Gotthardt; Sabine Kempe; Karsten Mäder; Claudia Grossmann; Michael Gekle
Journal:  Sci Rep       Date:  2014-12-11       Impact factor: 4.379

Review 6.  OPALS: A New Osimertinib Adjunctive Treatment of Lung Adenocarcinoma or Glioblastoma Using Five Repurposed Drugs.

Authors:  Richard E Kast; Marc-Eric Halatsch; Rafael Rosell
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.